title: Development of a mouse monoclonal antibody cocktail for post-exposure rabies prophylaxis in humans.
abstract: As the demand for rabies post-exposure prophylaxis (PEP) treatments has increased exponentially in recent years, the limited supply of human and equine rabies immunoglobulin (HRIG and ERIG) has failed to provide the required passive immune component in PEP in countries where canine rabies is endemic. Replacement of HRIG and ERIG with a potentially cheaper and efficacious alternative biological for treatment of rabies in humans, therefore, remains a high priority. In this study, we set out to assess a mouse monoclonal antibody (MoMAb) cocktail with the ultimate goal to develop a product at the lowest possible cost that can be used in developing countries as a replacement for RIG in PEP. Five MoMAbs, E559.9.14, 1112-1, 62-71-3, M727-5-1, and M777-16-3, were selected from available panels based on stringent criteria, such as biological activity, neutralizing potency, binding specificity, spectrum of neutralization of lyssaviruses, and history of each hybridoma. Four of these MoMAbs recognize epitopes in antigenic site II and one recognizes an epitope in antigenic site III on the rabies virus (RABV) glycoprotein, as determined by nucleotide sequence analysis of the glycoprotein gene of unique MoMAb neutralization-escape mutants. The MoMAbs were produced under Good Laboratory Practice (GLP) conditions. Unique combinations (cocktails) were prepared, using different concentrations of the MoMAbs that were capable of targeting non-overlapping epitopes of antigenic sites II and III. Blind in vitro efficacy studies showed the MoMab cocktails neutralized a broad spectrum of lyssaviruses except for lyssaviruses belonging to phylogroups II and III. In vivo, MoMAb cocktails resulted in protection as a component of PEP that was comparable to HRIG. In conclusion, all three novel combinations of MoMAbs were shown to have equal efficacy to HRIG and therefore could be considered a potentially less expensive alternative biological agent for use in PEP and prevention of rabies in humans.
authors.affiliation: WHO Collaborating Centre for Rabies Surveillance and Research, Friedrich-Loeffler-Institute, Federal Research Institute for Animal Health, Wusterhausen, Germany.
authors.forename: Thomas
authors.initials: T
authors.lastname: Müller
authors.forename: Bernhard
authors.initials: B
authors.lastname: Dietzschold
authors.forename: Hildegund
authors.initials: H
authors.lastname: Ertl
authors.forename: Anthony R
authors.initials: AR
authors.lastname: Fooks
authors.forename: Conrad
authors.initials: C
authors.lastname: Freuling
authors.forename: Christine
authors.initials: C
authors.lastname: Fehlner-Gardiner
authors.forename: Jeannette
authors.initials: J
authors.lastname: Kliemt
authors.forename: Francois X
authors.initials: FX
authors.lastname: Meslin
authors.forename: Richard
authors.initials: R
authors.lastname: Franka
authors.forename: Charles E
authors.initials: CE
authors.lastname: Rupprecht
authors.forename: Noël
authors.initials: N
authors.lastname: Tordo
authors.forename: Alexander I
authors.initials: AI
authors.lastname: Wanderler
authors.forename: Marie Paule
authors.initials: MP
authors.lastname: Kieny
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000191:economics / Q000276:immunology / Q000494:pharmacology*; D002460:Cell Line; D006224:Cricetinae; D006801:Humans; D051379:Mice; D009500:Neutralization Tests; D056990:Post-Exposure Prophylaxis / Q000191:economics / Q000379:methods*; D011818:Rabies / Q000188:drug therapy / Q000276:immunology / Q000517:prevention & control*; D011820:Rabies virus / Q000187:drug effects / Q000201:enzymology / Q000276:immunology
chemical_list: D000911:Antibodies, Monoclonal